Lexeo Therapeutics Reports Q4 Loss of $25.92 Million

Lexeo Therapeutics faces challenges with a Q4 loss. The company's earnings report indicates a loss of $25.92 million or -$0.78 per share, a worsening from last year's loss of $14.19 million. Investors may view this negatively.

Date: 24-03-2025

AI Rating: 4

Earnings Per Share (EPS): Lexeo Therapeutics reported an EPS of -$0.78 in the fourth quarter, which is slightly better than the previous year's -$0.86. However, the loss of $25.92 million raises concerns about the company's financial health.

Net Income: The net income was reported as -$25.92 million, which indicates a significant loss. This decline in net income compared to the prior year, where the loss was -$14.19 million, suggests deteriorating financial performance.

Investors often react negatively to increasing losses, and the comparison to last year's performance highlights a troubling trend. As the losses are widening, it could lead to reduced investor confidence in Lexeo Therapeutics.

Stocks: LXEO